Liraglutide

Development and Structure

Liraglutide is a 31-amino-acid GLP-1 analogue developed by Novo Nordisk and first approved by the FDA in January 2010 as Victoza for type 2 diabetes. Structurally, liraglutide is native GLP-1 with two modifications: a single lysine-to-arginine substitution at position 34, and a C16 palmitic acid chain attached via a gamma-glutamic acid linker to lysine 26. The fatty acid anchor binds albumin reversibly, extending the half-life from the two-minute native GLP-1 figure to approximately 13 hours — practical for once-daily subcutaneous dosing.

Liraglutide matters historically because it was the first commercially successful daily GLP-1 analogue, establishing the class as a mainstream diabetes therapy and laying the groundwork for later once-weekly and multi-receptor successors. A higher-dose formulation, Saxenda, was approved in December 2014 as the first GLP-1 agonist indicated specifically for chronic weight management.

Mechanism

Liraglutide activates the GLP-1 receptor with effects that are familiar across the class: glucose-dependent insulin secretion from pancreatic beta cells, glucagon suppression, delayed gastric emptying, and central appetite modulation via hypothalamic and brainstem GLP-1 receptors. Its pharmacodynamic profile is distinguishable from longer-acting agents like semaglutide principally by its shorter exposure window — peak and trough concentrations are more pronounced across a 24-hour dosing cycle, which shapes its side-effect timing.

Clinical Evidence

The liraglutide evidence base was built primarily by the LEAD program (Liraglutide Effect and Action in Diabetes) — a series of six Phase 3 trials (LEAD-1 through LEAD-6) that established glycemic efficacy, with HbA1c reductions around 1.0–1.5 percentage points, and favorable weight-loss signal versus comparators including glimepiride and insulin glargine.

Additional landmark trials:

• SCALE program. Supported the 3.0 mg obesity indication (Saxenda), with mean weight loss of roughly 8% of baseline over 56 weeks versus about 2.6% on placebo.
• LEADER (2016). Cardiovascular outcomes trial in over 9,000 patients with type 2 diabetes at high CV risk, reporting a 13% reduction in major adverse cardiovascular events — among the first GLP-1 agents to demonstrate CV benefit.
• Pediatric approval. In 2019, liraglutide became the first non-insulin diabetes therapy approved in the United States for type 2 diabetes in pediatric patients aged 10 and older.

Where Liraglutide Fits Now

Once-weekly agents — particularly semaglutide and tirzepatide — have largely displaced liraglutide as first-line GLP-1 therapy where formulary access permits, both because they produce larger weight loss and because weekly dosing improves adherence. Liraglutide retains relevance for three reasons: generic availability is arriving as Novo Nordisk patents lapse (the first authorized generic of Victoza launched in 2024), making it one of the few cost-accessible GLP-1 agents; it has the most established pediatric T2D data; and its shorter half-life allows faster washout in patients who need to discontinue due to tolerability.

Safety

Adverse-event profile mirrors the class — gastrointestinal symptoms dominant, concentrated during titration. Because liraglutide is dosed daily rather than weekly, GI side effects tend to be lower-intensity but more frequent in character compared to weekly agents, which some patients tolerate better and others find worse. Pancreatitis, gallbladder disease, and injection-site reactions occur at rates consistent with the class. The FDA label carries the boxed warning for rodent thyroid C-cell tumors, with the same MEN2 and medullary-thyroid-carcinoma contraindications as the rest of the GLP-1 class.

The Bottom Line

Liraglutide is the GLP-1 agent that made the class clinically ordinary. It is less potent than its weekly successors and requires daily dosing, but it has the longest post-marketing safety record, demonstrated cardiovascular benefit, pediatric data, and is the first member of the class to move toward meaningful generic pricing. For a broader overview of the oral and injectable incretin landscape, see our 2026 oral GLP-1 guide.